Leverage the captive audience our editorial team draws across our virtual and in-person events. Event sponsorships are key recognition opportunities alongside distinguished panelists who explore the biggest issues confronting the industry.
A special feature covering the latest in pharma innovation, manufacturing and development.
An Endpoints Day focused on drug discovery, featuring a panel session hosted by an Endpoints journalist with more sessions to be announced. This event will focus on research pipelines, emerging drug targets and the inflection point of research to development.
Cell & Gene Therapy Day will convene a series of expert panels to find out where the field stands today and explore funding, development and launch strategies to plot the path to commercialization.
An Endpoints Day focused on drug commercialization, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. This event will focus on trends in drug launches, marketing and sales.
Who are the women leading and influencing biopharma? Each year we seek out the up-and-comers moving the industry forward. Our in-depth profiles establish their stories into the fabric of an industry that isn’t changing fast enough to keep up with gender diversity.
An Endpoints Day focused on drug manufacturing, featuring a panel hosted by an Endpoints journalist with more sessions to be announced. We'll focus on the latest news and trends in drug supply chains, manufacturing developments and how the post-pandemic environment is affecting long-term capital expenditure planning.
Details coming soon
Charting the waters ahead for drug development in Europe — a day-long series of sessions on financing, R&D trends and regulatory issues that are central to the industry.
An Endpoints Day focused on clinical trials, featuring a panel session hosted by an Endpoints journalist and more. What are the latest trends in clinical trials? What regulatory curves are making the biggest waves? We’ll also take a look at how expectations from the industry and beyond are shifting the trial strategies of the future.
